First Time Loading...
S

SAB Biotherapeutics Inc
NASDAQ:SABS

Watchlist Manager
SAB Biotherapeutics Inc
NASDAQ:SABS
Watchlist
Price: 4.1 USD -4.43% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

SABS Price Targets Summary
SAB Biotherapeutics Inc

Wall Street analysts forecast SABS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SABS is 18.36 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.

SABS Lowest Forecast
Wall Street Target
6.06 USD
48% Upside
SABS Average Forecast
Wall Street Target
18.36 USD
348% Upside
SABS Highest Forecast
Wall Street Target
31.5 USD
668% Upside
Lowest
Price Target
6.06 USD
48% Upside
Average
Price Target
18.36 USD
348% Upside
Highest
Price Target
31.5 USD
668% Upside

SABS Last Price Targets
SAB Biotherapeutics Inc

The latest public price target was made on Apr 2, 2024 by Edward White from H.C. Wainwright , who expects SABS stock to rise by 46% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Edward White
H.C. Wainwright
6 USD
Upside 46%
1 month ago
Apr 2, 2024
SAB Biotherapeutics (SABS) PT Lowered to $6 at H.C. Wainwright following Q4 report
StreetInsider
Edward White
H.C. Wainwright
Price Target 6 USD
Upside/Downside 46%
View Source
SAB Biotherapeutics Inc Competitors:
Price Targets
Y
YS
YS Biopharma Co Ltd
468% Upside
ALERS
Eurobio Scientific SA
104% Upside
EXAS
Exact Sciences Corp
55% Upside
ASND
Ascendis Pharma A/S
31% Upside
Y
YS
YS Biopharma Co Ltd
468% Upside
ALERS
Eurobio Scientific SA
104% Upside
EXAS
Exact Sciences Corp
55% Upside
ASND
Ascendis Pharma A/S
31% Upside
CDMO
Avid Bioservices Inc
66% Upside
A
397030
AprilBio Co Ltd
84% Upside
L
2157
Lepu Biopharma Co Ltd
39% Downside
BIOA B
BioArctic AB
85% Upside

Revenue
Forecast

Revenue Estimate
SAB Biotherapeutics Inc

For the last 2 years the compound annual growth rate for SAB Biotherapeutics Inc's revenue is -81%.

-81%
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
SAB Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
SAB Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

See Also

Summary
SABS intrinsic value, competitors valuation, and company profile.
DCF Valuation
SABS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SABS stock valuation using valuation multiples.
Wall Street Estimates
SABS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SABS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SABS's stock price target?
Price Target
18.36 USD

According to Wall Street analysts, the average 1-year price target for SABS is 18.36 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.

ALPHA SPREAD
Join more than 133,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.